The company is a member of the Bracco Group, a highly innovative healthcare group and world leader in global integrated solutions for the diagnostic medical imaging field. The Bracco Group is headquartered in Milan, Italy. Its North American operations consist of Bracco Diagnostics and Bracco Research USA, both located in Princeton, New Jersey. Bracco Diagnostics is one of the fastest growing developers and marketers of diagnostic pharmaceuticals in North America, with products for various imaging applications, including Isovue® (iopamidol - X-ray contrast agent), ProHance® (gadoteridol - MRI contrast agent), SonoVue® (ultrasound contrast agent) and nuclear medicine products.
Gadoteridol has been available in Europe and the USA for several years. Holder of the Marketing Authorization: Bracco International B.V. - Strawinskylaan 3051 - 1077 ZX Amsterdam The Netherlands. (Contact: Kirk Deeter, Phone: +NL-303-838-8708)

MRI Contrast Agents:

[This entry is marked for removal.]

E-Z-EM, Inc. is headquartered in New York and develops, manufactures and markets diagnostic imaging products used by radiologists like the MRI bowel marker Gadolite® Oral Suspension.
In addition to medical diagnostics systems, the company's products include MR-compatible interventional devices, such as biopsy needles. E-Z-EM is also a third-party contract manufacturer of contrast media.
Bracco Diagnostics, Inc. , the US-based subsidiary of Bracco Imaging S.p.A. and part of the Bracco Group, announced in Oct. 2007 that it has entered into a merger agreement to acquire E-Z-EM, Inc. (NASDAQ: EZEM) for a total consideration of about $ 240 million. Upon completion of the procedure and subject to the approval of the regulatory authorities, Bracco Diagnostics Inc. will incorporate E-Z-EM.